TREatment of ATopic eczema (TREAT) Registry Taskforce

Team: TREAT Registry Taskforce Executive Committee: Carsten Flohr (Principal Investigator, UK), Phyllis Spuls (Principal Investigator, The Netherlands), Christian Apfelbacher (Germany), Alan Irvine (Ireland), and Jochen Schmitt (Germany); and Louise Gerbens, (The Netherlands)

Most patients with atopic eczema can be treated effectively with emollients and topical anti-inflammatory agents. However, the moderate-to-severe cases require more than these treatments to control their disease. In these cases photo- and systemic immunomodulating therapies are used.

The current evidence to guide clinical management for moderate-to-severe atopic eczema is based on a small body of randomized controlled trials and observational studies. There are no long-term, prospective and comparative data on these therapies in children or adults from large-scale multicentre cohort studies. In  absence of approved alternatives immunomodulatory therapies are frequently prescribed off-label.

Therefore, to improve quality of care, the TREAT Registry Taskforce aims to capture long-term prospective observational data on the use of photo- and systemic immunomodulating therapies in real-life pediatric and adult patients with atopic eczema in national registries. A standardized methodological approach across participating centres and countries will enhance direct comparability of individual country data and allow data pooling between countries.

There is consensus amongst a multidisciplinary, multinational team of stakeholders on the What (eDelphi and consensus meeting), How and When to measure of a core dataset and a web-based database is being developed.

Website: See


1 The international TREatment of ATopic eczema (TREAT) Registry Taskforce: an initiative to harmonise data collection across national atopic eczema photo- and systemic therapy registries. JID 2017

2 TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries. Trials 2017

3 Usage and effectiveness of systemic treatments in adults with severe atopic eczema: First results of the German Atopic Eczema Registry TREATgermany. Journal der Deutschen Dermatologischen Gesellschaft (JDDG) 2017


TREAT surveys

Anecdotally, there is wide variation in treatment approaches between clinicians in the way they treat severe atopic eczema; i.e. eczema that has not responded to conventional topical and/or light therapy. Three surveys have been conducted to gather information on how severe atopic eczema in children in Europe and adults in the UK , Canada and the US is treated, not only to inform clinical practice but also to potentially aid the design of an intervention study with different systemic immunomodulating drugs. Currently, a similar survey is being conducted for adult patients across Europe (supported by the EADV).



1 Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M, et al. The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013;169:901-9.

2 Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ, DCTN. cwUTatU. Treatment of moderate-to-severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists. Br J Dermatol 2017;176:1617-1623.

3 Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara-Corrales I, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. J Am Acad Dermatol 2017;76:281-5.